Human Challenge Study to Evaluate the Efficacy of MV-012-968 Vaccine

A Randomised, Phase 2a, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Prophylactic Efficacy of MV-012-968 Against Respiratory Syncytial Virus (RSV) Infection in the Virus Challenge Model.

The purpose of this research study is to evaluate whether the investigational, live attenuated, intranasally delivered vaccine MV-012-968 ('study vaccine') may have prophylactic efficacy against symptomatic RSV infection when administered to adults 18-45 years of age in the Human Viral Challenge model.

Study Overview

• Status: Completed
• Conditions: RSV Infection
• Intervention / Treatment: Other: Placebo; Biological: MV-012-968

• Study Type: Interventional
• Enrollment (Actual): 60
• Phase: Phase 2

Contacts and Locations

Study Locations

• United Kingdom
  • London, United Kingdom, E1 2AX
    • hVIVO Services Ltd

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 45 years (ADULT)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Key Inclusion Criteria:

1. An informed consent document signed and dated by the participant and the Investigator.
2. Aged between 18 and 45 years old on the day of signing the consent form.
3. In good general health with no history, or current evidence, of clinically significant medical conditions (including respiratory, cardiac and immunodeficiency), and no clinically significant test abnormalities that will interfere with participant safety, as defined by medical history, physical examination (including vital signs), electrocardiogram (ECG), and routine laboratory tests as determined by the Investigator.
4. A documented medical history prior to enrolment.
5. Females of child bearing potential must have a negative pregnancy test prior to enrollment.
6. Females and Males must agree to adhere to the highly effective contraceptive requirements of the study from 2 weeks prior to the first study visit until 90 days after the date of study vaccination.
7. Sero-suitable to the challenge virus, as defined in the study Analytical Plan.

Exclusion Criteria:

1. History of symptoms or signs suggestive of upper or lower respiratory tract infection within 4 weeks prior to the first study visit
2. Rhinitis which is clinically active
3. History of moderate to severe rhinitis
4. Acute sinusitis during Screening
5. Use of corticosteroid in respiratory tract (e.g. nasal or inhaled steroid) in the 30 days leading up to study vaccination
6. Females who are breastfeeding or have been pregnant within 6 months prior to the study
7. Participants who have smoked ≥ 10 pack years at any time [10 pack years is equivalent to one pack of 20 cigarettes a day for 10 years])
8. Positive human immunodeficiency virus (HIV), active hepatitis A (HAV), B (HBV), or C (HCV) test
9. Those employed or immediate relatives of those employed at hVIVO or the Sponsor
10. Participants may not live or work in direct close contact with, or live with anyone whose work brings them into direct close contact with, children under 2 years of age
11. Any other finding that, in the opinion of the Investigator, deems the participant unsuitable for the study

Study Plan

How is the study designed?

Design Details

• Primary Purpose: PREVENTION
• Allocation: RANDOMIZED
• Interventional Model: PARALLEL
• Masking: QUADRUPLE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: MV-012-968; Dose: 1 x10^6 Plaque Forming Unit (PFU), given intranasally, followed approximately 28 days later by inoculation with RSV-A (Memphis 37b).	Biological: MV-012-968; MV-012-968 is a recombinant, live attenuated RSV vaccine.
PLACEBO_COMPARATOR: Placebo; Sodium Chloride 0.9% w/v intravenous infusion B.P (Normal Saline) matched to reference article product, given intranasally.	Other: Placebo; Saline solution

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Frequency of symptomatic RSV infection, as defined as the occurrence of both:	At least 1 quantifiable plaque assay sample in nasal wash specimens and; Symptoms meeting either: (i) a symptom of any grade from 2 different symptom categories from the participant Symptom Diary Card [SDC] (Upper Respiratory, Lower Respiratory, Systemic) or (ii) at least 1 Grade 2 upper or lower respiratory symptom from the participant SDC	10 days (days 2 to 12)

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Frequency of symptomatic RSV infection, as defined as occurrence of both:	Two Quantifiable RT-qPCR samples on 2 consecutive days (i.e. at least 1 on each of 2 consecutive days) in nasal wash specimens and; Symptoms meeting either: (i) a symptom of any grade from 2 different symptom categories from the SDC (Upper Respiratory, Lower Respiratory, Systemic) or (ii) at least 1 Grade 2 upper or lower respiratory symptom from the participant SDC	10 days (days 2 to 12)
Frequency of RSV infection, as defined as the occurrence of 2 quantifiable RT-qPCR samples on 2 consecutive days (i.e. at least 1 on each of 2 consecutive days) in nasal wash specimens		10 days (Day 2 to 12)
Frequency of RSV infection, as defined as the occurrence of at least 1 quantifiable plaque assay sample in nasal wash specimens		10 days (Day 2 to 12)
Mean daily total symptom score using the SDC		10 days (Day 2 to 12)
Mean daily weight of nasal (mucus) discharge		10 days (Day 2 to 12)
RSV load Area Under the Curve (AUC), as measured by RT-qPCR analysis of nasal wash specimens		10 days (Day 2 to 12)
Peak RSV load, as measured by RT-qPCR of nasal wash specimens		10 days (Day 2 to 12)
Frequency of solicited adverse events (AEs) as reported in the Subject Vaccination Diary Card, categorized by severity. Solicited AEs are predefined AEs that may occur after study vaccine administration.		Time Frame: 7 days (Day -28 to -21)
Frequency of unsolicited AEs after study vaccination, categorized by severity and by study vaccine relatedness.	Unsolicited AEs are any untoward medical occurrences in a participant administered the study vaccine, regardless of causal relationship to the study vaccine. Unsolicited AEs can include unfavorable and unintended signs (including abnormal laboratory findings), symptoms, or diseases temporally associated with the use of the study vaccine.	28 days (Day -28 to 0)
Frequency of unsolicited AEs after RSV-A challenge, categorized by severity and by study vaccine relatedness.		29 days (Day 0 to 28)
Frequency of serious AEs (SAEs) after study vaccination, categorized by study vaccine relatedness.	SAEs are AEs, whether considered causally related to the study vaccine or not, that threaten life or result in any of the following: death, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions, or congenital anomaly/birth defect.	180 days (Day -28 to 152)
Frequency of medically attended AEs (MAEs) after study vaccination, categorized by study vaccine relatedness.	MAEs are AEs, whether considered causally related to the study vaccine or not, with unscheduled medically attended visits, such as urgent care visits, acute primary care visits, emergency department visits, or other previously unplanned visits to a medical provider. Scheduled medical visits such as routine physicals, wellness checks, 'checkups', and vaccinations, are not considered MAEs	180 days (Day -28 to 152)

Collaborators and Investigators

• Sponsor: Meissa Vaccines, Inc.
• Collaborators: Hvivo
• Investigators: Principal Investigator: Mariya Kalinova, MD, hVIVO Services Ltd

Study record dates

Study Major Dates

• Study Start (ACTUAL): December 29, 2020
• Primary Completion (ACTUAL): May 7, 2021
• Study Completion (ACTUAL): September 9, 2021

Study Registration Dates

• First Submitted: December 28, 2020
• First Submitted That Met QC Criteria: December 28, 2020
• First Posted (ACTUAL): December 30, 2020

Study Record Updates

• Last Update Posted (ACTUAL): August 4, 2022
• Last Update Submitted That Met QC Criteria: August 1, 2022
• Last Verified: August 1, 2022

More Information

Terms related to this study

• Keywords: safety; vaccine; intranasal; RSV; efficacy; Phase 2; challenge; live attenuated
• Additional Relevant MeSH Terms: RNA Virus Infections; Virus Diseases; Paramyxoviridae Infections; Mononegavirales Infections; Pneumovirus Infections; Infections; Respiratory Syncytial Virus Infections
• Other Study ID Numbers: MV-004; 2020-002848-22 (EUDRACT_NUMBER)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes